Dividend Medtech Giant Medtronic Is Built to Survive Any Market Crash

Core Insights - Medtronic is a consistent dividend payer with a 48-year history of increasing its dividend, making it a unique player in the healthcare stock sector [1][7] - The company operates in a recession-resistant market, providing essential medical devices and treatments that are often non-negotiable for patients [2] - Medtronic has only experienced two declines in annual revenue since 2000, with a 5.4% drop in fiscal year 2020 due to the COVID pandemic and a 1.4% decrease in 2023 attributed to currency fluctuations and supply chain issues [4] - The company has four strong business units: cardiovascular, medical-surgical, neuroscience, and diabetes, although the diabetes unit is set to be spun off [5] - Medtronic has maintained annual net income for over 60 years, showcasing its financial stability despite some fluctuations in profitability [6] - The current dividend yield is nearly 3%, which is more than double the average yield of S&P 500 stocks, highlighting the company's commitment to returning value to shareholders [7] - Despite its strong fundamentals, Medtronic's stock has underperformed the S&P 500 index for several years due to frequent restructuring and competition from other healthcare companies [8] - The company has received FDA clearance for its Hugo robotic-assisted surgery system, indicating potential growth opportunities in the future [10] - Expectations are high for Medtronic to outperform the S&P 500 in the coming years, suggesting a potential investment opportunity [11]